Por favor, inténtelo con una nueva búsqueda
El objetivo del Fondo es preservar el capital y lograr un crecimiento de este a largo plazo invirtiendo en acciones de empresas de todo el mundo de los sectores biotecnológico, de diagnóstico y de ciencias de la vida. El Fondo está ampliamente diversificado por países, por sectores biotecnológicos y por capitalización de mercado. El Fondo trata de superar la rentabilidad de un índice de referencia, el NASDAQ Biotechnology Index. El Fondo puede invertir en instrumentos financieros derivados con fines de cobertura, para reducir riesgos, gestionar el Fondo con más eficiencia o adquirir exposición a títulos de modo más eficaz.
Nombre | Título | Desde | Hasta |
---|---|---|---|
David Pinniger | Portfolio Manager | 2013 | Ahora |
Biografía | David Pinniger joined Polar Capital in August 2013 as lead manager of the Biotechnology Fund within the healthcare team. Prior to joining Polar Capital, for five years David was portfolio manager of the International Biotechnology Trust at SV Life Sciences. He also previously spent three years working at venture capital firm Abingworth as an analyst managing biotechnology investments held across the firm’s venture and specialist funds, and four years at Morgan Stanley as an analyst covering the European pharmaceuticals and biotechnology sector. David received a first class honours degree in human sciences from Oxford University in 1999 and is a CFA charterholder. | ||
Gareth Powell | Portfolio Manager | 2013 | Ahora |
Biografía | Gareth Powell joined Polar Capital in 2007 to establish the healthcare investment team. He is joint manager of the Healthcare Opportunities Fund. He joined Framlington in 1999, later becoming a portfolio manager on the Framlington Health Fund. In 2002, Gareth helped launch the Framlington Biotech Fund, which he managed until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder. | ||
Daniel Mahony | Portfolio Manager | 2013 | 2019 |
Biografía | Daniel Mahony Ph.D. joined Polar Capital to establish the healthcare investment team in 2007. He is joint manager of the Healthcare Opportunities Fund and lead manager of the Healthcare Blue Chip Fund. Prior to joining Polar Capital, he was head of the European healthcare research team at Morgan Stanley, covering the European biotechnology, medical technology and healthcare services sectors. He also previously worked in New York for ING Barings Furman Selz following the US biotechnology sector. Before working in the investment field, Daniel worked as a research scientist for seven years with the majority of his time at Schering Plough Corporation in California. Daniel received his PhD from Cambridge University in 1995 and a first class honours degree in biochemistry from Oxford University in 1991. |
¿Está seguro de que desea bloquear a %USER_NAME%?
Al hacerlo, ni usted ni %USER_NAME% podrán ver las publicaciones del otro en Investing.com.
Se ha agregado correctamente a %USER_NAME% a su lista de usuarios bloqueados
Acaba de desbloquear a esta persona; tiene que esperar 48 horas para poder bloquearla de nuevo.
Díganos qué piensa de este comentario
Gracias
Su denuncia será examinada por nuestros moderadores